About Dr. Zhao Weiwei
Dr. Zhao Weiwei (赵苇苇) is an Associate Chief Physician (副主任医师) in the Department of Medical Oncology at Fudan University Shanghai Cancer Center (FUSCC). With extensive experience in the comprehensive treatment of advanced and late-stage malignancies, Dr. Zhao specializes in gastric cancer, pancreatic cancer, colorectal cancer, and a broad range of other solid tumors. Her clinical philosophy centers on a dual commitment: extending survival while meaningfully preserving and improving quality of life for patients living with cancer.
Dr. Zhao's practice reflects a holistic approach to oncology that goes beyond tumor response rates. She places particular emphasis on symptom management, nutritional support, and palliative care integration — recognizing that for patients with advanced disease, how they live through treatment is as important as how long they live. This patient-centered philosophy, combined with her expertise in individualized systemic therapy, makes her a trusted clinician for international patients navigating complex, multi-line treatment journeys.
Clinical Expertise
- Gastric cancer — comprehensive systemic treatment including chemotherapy, HER2-targeted therapy (trastuzumab), anti-VEGF therapy (ramucirumab), and immunotherapy (pembrolizumab, nivolumab) for advanced and metastatic disease
- Pancreatic cancer — medical oncology management including FOLFIRINOX, gemcitabine + nab-paclitaxel, and emerging targeted agents for locally advanced and metastatic pancreatic ductal adenocarcinoma
- Colorectal cancer — systemic therapy for advanced rectal and colon cancer, including FOLFOX, FOLFIRI, bevacizumab, cetuximab, and immunotherapy for MSI-H/dMMR tumors
- Advanced tumor comprehensive treatment — multi-line treatment planning for patients who have progressed on prior therapies, integrating novel agents and clinical trial options
- Tumor-related symptom control — management of cancer pain, nausea, fatigue, cachexia, ascites, and other symptoms that significantly impact quality of life
- Individualized treatment planning — tailoring systemic therapy to each patient's tumor molecular profile, performance status, comorbidities, and personal goals of care
- Palliative oncology — integrating supportive and palliative care principles into active cancer treatment to optimize patient wellbeing throughout the disease course
Why Dr. Zhao Weiwei?
For patients with advanced gastric, pancreatic, or colorectal cancer — particularly those who have already received one or more lines of treatment — finding a medical oncologist who can design an effective next-line strategy while managing the cumulative burden of symptoms and side effects is critical. Dr. Zhao's dual expertise in tumor treatment and symptom control makes her uniquely suited to this challenge.
Her emphasis on quality of life is not a compromise on oncological ambition — it is a recognition that patients who are better supported through treatment tolerate more therapy, maintain better performance status, and ultimately achieve better outcomes. For international patients who may be far from home and family support networks, this holistic approach is especially valuable.
At FUSCC, Dr. Zhao works within one of China's most comprehensive oncology ecosystems, with access to the latest approved therapies, an active clinical trials program, and a multidisciplinary tumor board that reviews complex cases across surgery, radiation, and medical oncology. This environment allows her to offer patients treatment options that may not be available at centers with less research infrastructure.
Hospital: Fudan University Shanghai Cancer Center (FUSCC)
FUSCC is China's premier dedicated cancer hospital, affiliated with Fudan University School of Medicine and consistently ranked among the top oncology centers in Asia. The hospital sees over 100,000 new cancer patients annually and maintains one of the most active clinical trials programs in China, with participation in international studies across all major tumor types. FUSCC's medical oncology department is staffed by subspecialty-trained physicians with deep expertise in specific tumor types, ensuring that patients receive care from specialists rather than generalists.
About Advanced Gastric, Pancreatic & Colorectal Cancer
Advanced gastrointestinal cancers present unique challenges due to their aggressive biology, frequent late-stage diagnosis, and the complexity of managing both tumor progression and treatment-related symptoms. Key facts for international patients:
- Gastric cancer: HER2 testing is essential — HER2-positive patients benefit from trastuzumab-based regimens; PD-L1 CPS score guides immunotherapy eligibility; claudin 18.2 is an emerging target with zolbetuximab now approved in some markets
- Pancreatic cancer: FOLFIRINOX and gemcitabine + nab-paclitaxel remain the backbone of first-line treatment; BRCA/PALB2 mutations open the door to PARP inhibitor maintenance; KRAS inhibitors are in active clinical development
- Colorectal cancer: RAS/RAF mutation status determines eligibility for EGFR inhibitors (cetuximab, panitumumab); MSI-H/dMMR tumors respond well to immunotherapy (pembrolizumab); BRAF V600E mutations are targetable with encorafenib + cetuximab
- Symptom management: cancer-related pain, malnutrition, and fatigue are independent predictors of survival and quality of life; proactive symptom management improves both
- Nutritional support: pancreatic enzyme replacement, nutritional supplementation, and appetite stimulation are integral to maintaining treatment tolerance in GI cancer patients
What to Prepare Before Your Consultation
To enable Dr. Zhao's team to conduct a thorough remote case review, international patients should prepare:
- CT scan of the chest, abdomen, and pelvis with contrast (DICOM format, within 3 months)
- Pathology report with full immunohistochemistry panel (HER2, PD-L1, MSI/MMR, RAS/RAF/BRAF for colorectal)
- Tumor markers: CA 19-9, CEA, CA 72-4, AFP as relevant
- Summary of all prior treatment lines with regimens, dates, and best response
- Genetic testing results (germline and somatic) if available
- Current performance status (ECOG), weight, and nutritional assessment
- Current medications and any ongoing side effects from prior treatment
How CMCS Can Help
China Medical Concierge Shanghai (CMCS) coordinates access to Dr. Zhao Weiwei and the FUSCC medical oncology team for international patients. Our services include:
- Remote case review and pre-consultation assessment before you travel
- Priority appointment scheduling with Dr. Zhao's team at FUSCC
- Full translation of medical records, pathology reports, and treatment plans
- In-hospital accompaniment by a dedicated English-speaking case manager
- Accommodation, airport transfer, and logistics coordination in Shanghai
- Post-discharge follow-up and remote consultation support after returning home
Contact us to begin your case review:
📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com
댓글 0개